NCT03491345: K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1, EBV+, MSI-H, POLE, POLD
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have PD-L1+ mutation, EBV+ mutation, MSI-H mutation, or POLE/POLD1 mutation
Exclusions: Previous treatment with immune checkpoint inhibitor; Subjects with brain metastases, except those that meet certain criteria- see trial for details

Comments are closed.

Up ↑